Last $3.02 USD
Change Today +0.01 / 0.33%
Volume 21.1K
LPTN On Other Exchanges
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

lpath inc-class a (LPTN) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/25/13 - $5.36
52 Week Low
08/19/14 - $2.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LPATH INC-CLASS A (LPTN)

Related News

No related news articles were found.

lpath inc-class a (LPTN) Related Businessweek News

No Related Businessweek News Found

lpath inc-class a (LPTN) Details

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies for treating a range of human diseases primarily in the United States. The company’s lead product candidate includes iSONEP, a monoclonal antibody against sphingosine-1-phosphate (S1P), which has completed Phase I clinical trials to treat wet age-related macular degeneration; and is in Phase 1b/2a clinical trials to treat retinal pigment epithelium detachment. Its products under development also comprise ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid S1P that is in Phase 2a clinical trials for the treatment for renal cell carcinoma; various forms of cancer; and other angiogenic-related and inflammatory-oriented indications. In addition, the company is developing Lpathomab, a mAb against lysophosphatidic acid, which is in pre-clinical trials intended for the treatment of neuropathic pain, traumatic brain injury, spinal cord injury, and fibrosis cancer. It has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.

24 Employees
Last Reported Date: 03/18/14

lpath inc-class a (LPTN) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $535.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $365.3K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $215.4K
Senior Vice President of Research
Total Annual Compensation: $215.4K
Compensation as of Fiscal Year 2013.

lpath inc-class a (LPTN) Key Developments

Lpath Mulls Acquisitions

Lpath Inc. (NasdaqCM:LPTN) is seeking acquisitions. Lpath Inc. has completed a follow-on equity offering in the amount of $12.53 million. Lpath said that it plans to raise funds via direct offering and plans to use part of proceeds for acquisitions too. Lpath said, "Lpath may also use a portion of the net proceeds to invest in or acquire businesses or technologies that it believes are complementary to its own, although it has no current plans, commitments or agreements with respect to any acquisitions as of the date hereof."

Lpath Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 08:30 AM

Lpath Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 08:30 AM. Venue: The Palace Hotel, San Francisco, CA 94105, United States. Speakers: Scott R. Pancoast, Founder, Chief Executive Officer, President, Director and Member of R & D Advisory Committee.

Lpath, Inc. Reports Interim Results in Phase 2a Single-Arm, Open-Label Trial

Lpath Inc. reported interim results in a Phase 2a single-arm, open-label trial where ASONEP(TM) is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent(R)/sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor(R)/everolimus), with a maximum of three failed treatments in all. This patient population is considered "last line," and the literature suggests cancer progression in this population within a one-to-two month time frame. The company has enrolled 26 patients in the study. ASONEP has a favorable safety profile thus far, with no serious adverse events (SAEs) deemed to be drug-related. The first 17 patients were initiated at a dose of 15 mg/kg. Of these "lower-dose" patients: 7 had progressive disease at or before the end of four months; 8 were progression-free at the four-month mark (with 1 of these patients deemed a partial responder per Response Evaluation Criteria in Solid Tumors (RECIST) criteria and with 3 of these patients experiencing reduced tumor volume, but not enough to be categorized as a RECIST-based partial responder); and 2 exited the study due to SAEs unrelated to the drug prior to the four-month mark (and are not considered evaluable). Notably, of the 8 patients that were stable or better as of month four, 2 are now in their fifteenth month on the study, 1 is in month thirteen, and 1 is in month ten. An additional patient was stable through month seven, but then missed six treatments during a vacation, and shortly thereafter progressed. The next 9 patients were initiated at a dose of 24 mg/kg. Of these higher-dose patients: 4 had progressive disease at or before the end of four months; 2 were progression-free at the four-month mark (with 1 of these 2 deemed a partial responder per RECIST criteria); and the remaining 3 have not yet reached their four-month mark.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPTN:US $3.02 USD +0.01

LPTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LPTN.
View Industry Companies

Industry Analysis


Industry Average

Valuation LPTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.0x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LPATH INC-CLASS A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at